Pharmaceutical firm Lupin announced that it has received tentative approval from the US health regulator to market its generic version of Dolutegravir and Rilpivirine tablets used in treatment of HIV infection, in an exchange filing.
The tentative approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Dolutegravir and Rilpivirine tablets of strength 50 mg/25 mg, Lupin said in the filing.
The Dolutegravir and Rilpivirine tablets, 50 mg/25 mg had estimated annual sales of USD 666 million in the US, the company said citing IQVIA MAT September 2022 data.
'People Matter Far More Than Its Success': Deepika Padukone Pens Cryptic Note After Kalki 2 Exit, Confirms King With Shah Rukh Khan
'Rohit Bhai Ne Bamboo...': Yashasvi Jaiswal On His Verbal Fight With Sam Konstas During Border Gavaskar Trophy 2024-25
India Is The Biggest Textile Market In The World With 1.4 Billion Consumers: Union Minister Margherita
Multiple Delhi Schools Evacuated After Bomb Threats; No Explosives Found
